Abstract 1785P
Background
Androgen deprivation therapy (ADT) is associated with increased fracture risk, due to bone loss and bone quality impairment, as well as with profound alterations in body composition favoring the transition to sarcopenic obesity. Additional metabolic effects of next generation hormonal agents (NGHA) in combination with ADT have been poorly studied.
Methods
BonEnza (NCT03336983) is a prospective phase II trial in which mHSPC patients were randomized to receive either ADT plus enzalutamide (E arm) or the same combination with the addition of zoledronic acid (EZ arm). Bone mineral density (BMD), trabecular bone score (TBS), fat body mass (FBM) and lean body mass (LBM) were assessed at baseline and after 18 months using dual energy x-ray absorptiometry (DEXA) scan.
Results
From February 2018 to December 2022, a total of 89 patients (46 from EZ arm and 43 from E arm), had paired DEXA evaluation at both timepoints. Femoral BMD and TBS significantly reduced in E arm (-9.1%, p<0.001; -3.1%, p=0.001, respectively), while they increased in EZ arm (5.3%, p<0.001; 2.8%, p=0.008, respectively). FBM increased by 22.7% (p<0.001) and LBM decreased by 6.3% (p<0.001) after 18 months of therapy, irrespective of study arm.
Conclusions
The addition of enzalutamide to ADT is associated with a marked reduction in BMD and impaired bone quality as measured by TBS. Both effects are prevented by zoledronic acid administration. The reduction in LBM and increase in FBM were doubled compared to previous observations with ADT alone, putting patients at an elevated risk of sarcopenic obesity.
Clinical trial identification
NCT03336983.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Astellas.
Disclosure
A. Dalla Volta: Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Institutional, Research Funding: Janssen, Ipsen, Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
1229P - Selective phenotypic and genotypic evaluation of circulating glial cells for improved diagnosis of glial malignancies
Presenter: Sewanti Limaye
Session: Poster session 14
1230P - hPG80 (circulating progastrin) is a new blood-based biomarker for diagnosis of early-stage non-small cell lung cancers
Presenter: Paul Hofman
Session: Poster session 14
1231P - Machine learning prediction of the case-fatality of COVID-19 and risk factors for adverse outcomes in patients with non-small cell lung cancer
Presenter: Yeji Jung
Session: Poster session 14
1232P - Analytic analysis of PanSeer7, a targeted bisulfite sequencing assay for blood-based multi-cancer detection for cancer early detection and tissue-of-origin identification
Presenter: Xinrong Yang
Session: Poster session 14
1233P - Accurate prediction of gastrointestinal cancer tissue of origin using comprehensive plasma cell-free DNA fragmentomics features
Presenter: Xinrong Yang
Session: Poster session 14
1234P - HistoMate: Automated preprocessing software for digital histopathology image to enhance deep learning
Presenter: Jinok Lee
Session: Poster session 14
1235P - Enrichment of rare cancers in pragmatic precision cancer medicine trial: Experience from IMPRESS-Norway
Presenter: Aaslaug Helland
Session: Poster session 14
1236P - Feasibility of online symptom monitoring to detect lung cancer relapse in Poland
Presenter: Ewa Pawlowska
Session: Poster session 14
1237P - Design and validation of a custom next-generation sequencing panel in melanoma, glioma and gastrointestinal stromal tumor
Presenter: Xiaoyan Zhou
Session: Poster session 14
1238P - Detecting driver mutations by AmoyDx 11-gene PCR with high concordance with next-generation sequencing in Chinese non-small cell lung cancer patients
Presenter: Dongmei Lin
Session: Poster session 14